SEC Comment Letter 0000000000-24-004309 to IGC Pharma, Inc. (IGC)
IGC Pharma, Inc.
Date: April 19, 2024 · CIK: 0001326205 · Accession: 0000000000-24-004309
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-278775
Letter
United States securities and exchange commission logo April 19, 2024 Ram Mukunda President and Chief Executive Officer IGC Pharma, Inc. 10224 Falls Road Potomac, Maryland 20854 Re:IGC Pharma, Inc. Registration Statement on Form S-3 Filed April 18, 2024 File No. 333-278775 Dear Ram Mukunda: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Spencer G. Feldman, Esq.
Show Raw Text
United States securities and exchange commission logo
April 19, 2024
Ram Mukunda
President and Chief Executive Officer
IGC Pharma, Inc.
10224 Falls Road
Potomac, Maryland 20854
Re:IGC Pharma, Inc.
Registration Statement on Form S-3
Filed April 18, 2024
File No. 333-278775
Dear Ram Mukunda:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Spencer G. Feldman, Esq.